Research ArticleSystemic Sclerosis

Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years

Janet E. Pope, Kobina Quansah, Shazia Hassan, Soo Jin Seung, Jason Flavin and Martin Kolb
The Journal of Rheumatology September 2021, 48 (9) 1427-1434; DOI: https://doi.org/10.3899/jrheum.201049

REFERENCES

  1. 1.↵
    1. Ranque B,
    2. Mouthon L
    . Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-18.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kowal-Bielecka O,
    2. Fransen J,
    3. Avouac J,
    4. Becker M,
    5. Kulak A,
    6. Allanore Y, et al.
    Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327-39.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Hoffmann-Vold AM,
    2. Midtvedt Ø,
    3. Molberg Ø,
    4. Garen T,
    5. Gran JT
    . Prevalence of systemic sclerosis in south-east Norway. Rheumatology 2012;51:1600-5.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Airò P,
    2. Tabaglio E,
    3. Frassi M,
    4. Scarsi M,
    5. Danieli E,
    6. Rossi M
    . Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 2007;25:878-80.
    OpenUrlPubMed
  5. 5.↵
    1. Furst DE,
    2. Fernandes AW,
    3. Iorga SR,
    4. Greth W,
    5. Bancroft T
    . Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol 2012;39:784-6.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Thompson AE,
    2. Pope JE
    . Increased prevalence of scleroderma in Southwestern Ontario: a cluster analysis. J Rheumatol 2002;29:1867-73.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Mayes MD,
    2. Lacey JV,
    3. Beebe-Dimmer J,
    4. Gillespie BW,
    5. Cooper B,
    6. Laing TJ, et al.
    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Strickland G,
    2. Pauling J,
    3. Cavill C,
    4. Shaddick G,
    5. McHugh N
    . Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 2013;32:1533-9.
    OpenUrl
  9. 9.↵
    1. Bauer PR,
    2. Schiavo DN,
    3. Osborn TG,
    4. Levin DL,
    5. St Sauver J,
    6. Hanson AC, et al.
    Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 2013;144:571-7.
    OpenUrl
  10. 10.↵
    1. Schoenfeld SR,
    2. Castelino FV
    . Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015;41:237-48.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Herzog E,
    2. Mathur A,
    3. Tager A,
    4. Feghali-Bostwick C,
    5. Schneider F,
    6. Varga J
    . Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014;66:1967-78.
    OpenUrl
  12. 12.↵
    1. Vonk MC,
    2. Broers B,
    3. Heijdra YF,
    4. Ton E,
    5. Snijder R,
    6. van Dijk APJ, et al.
    Systemic sclerosis and its pulmonary complications in the Netherlands: an epidemiological study. Ann Rheum Dis 2009;68:961-5.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mulla E,
    2. Shaffu S,
    3. Hassan W
    . A comparative study of the difference in clinical manifestations and disease outcomes between South Asian and Caucasian patients with systemic sclerosis in a large NHS trust, within the United Kingdom [abstract]. Ann Rheum Dis 2015;74:1128.
    OpenUrl
  14. 14.↵
    1. Steele R,
    2. Hudson M,
    3. Lo E,
    4. Baron M; Canadian Scleroderma Research Group
    . Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519-24.
    OpenUrlCrossRef
  15. 15.↵
    1. Muangchan C; Canadian Scleroderma Research Group;
    2. Baron M,
    3. Pope J
    . The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol 2013;40:1545-56.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Bergamasco A,
    2. Hartmann N,
    3. Wallace L,
    4. Verpillat P
    . Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol 2019;11:257-73.
    OpenUrlPubMed
  17. 17.↵
    1. Ryerson CJ,
    2. O’Connor D,
    3. Dunne JV,
    4. Schooley F,
    5. Hague CJ,
    6. Murphy D, et al.
    Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 2015;148: 1268-75.
    OpenUrlPubMed
  18. 18.↵
    1. Statistics Canada
    . Population estimates on July 1st, by age and sex—Ontario. [Internet. Accessed May 12, 2021]. Available from: www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501&pickMembers%5B0%5D=1.7&pickMembers%5B1%5D=2.1
  19. 19.↵
    1. Juurlink D,
    2. Preyra C,
    3. Croxford R,
    4. Chong A,
    5. Austin P,
    6. Tu J, et al.
    Canadian Institute for Health Information Discharge Abstract Database: a validation study. ICES investigative report 2006. Toronto: Institute for Clinical Evaluative Sciences; 2006.
  20. 20.↵
    1. De Almeida Chaves S,
    2. Derumeaux H,
    3. Do Minh P,
    4. Lapeyre-Mestre M,
    5. Moulis G,
    6. Pugnet G
    . Assessment of the accuracy of using ICD-10 codes to identify systemic sclerosis. Clin Epidemiol 2020;12:1355-9.
    OpenUrl
  21. 21.↵
    1. Hutchinson JP,
    2. McKeever TM,
    3. Fogarty AW,
    4. Navaratnam V,
    5. Hubbard RB
    . Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc 2014;11:1176-85.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Jones N,
    2. Schneider G,
    3. Kachroo S,
    4. Rotella P,
    5. Avetisyan R,
    6. Reynolds MW
    . A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:256-60.
    OpenUrl
  23. 23.↵
    1. Institute of Clinical Evaluative Sciences
    . Evidence Guiding Healthcare. [Internet. Accessed May 12, 2021]. Available from: www.ipc.on.ca/wp-content/uploads/2017/07/2011-pe-ices-rpt.pdf
  24. 24.↵
    1. Bernatsky S,
    2. Joseph L,
    3. Pineau CA,
    4. Belisle P,
    5. Hudson M,
    6. Clarke AE
    . Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009;61:400-4.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Barnabe C,
    2. Joseph L,
    3. Edworthy S,
    4. Belisle P,
    5. Svenson L,
    6. Labrecque J, et al.
    Scleroderma prevalence in Alberta: a population-based assessment [abstract]. J Rheumatol 2011;38:1151.
    OpenUrl
  26. 26.↵
    1. Hussein H,
    2. Lee P,
    3. Chau C,
    4. Johnson SR
    . The effect of male sex on survival in systemic sclerosis. J Rheumatol 2014;41:2193-200.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Rubio-Rivas M,
    2. Royo C,
    3. Simeón CP,
    4. Corbella X,
    5. Fonollosa V
    . Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:208-19.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Su R,
    2. Bennett M,
    3. Jacobs S,
    4. Hunter T,
    5. Bailey C,
    6. Krishnan E, et al.
    An analysis of connective tissue disease-associated interstitial lung disease at a US tertiary care center: better survival in patients with systemic sclerosis. J Rheumatol 2011;38:693-701.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Canadian Cancer Society
    . Canadian Cancer Statistics 2019. [Internet. Accessed May 12, 2021]. Available from: cancer.ca/Canadian-Cancer-Statistics-2019-EN
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

INTERSTITIAL LUNG DISEASE
PREVALENCE
SURVIVAL
SYSTEMIC SCLEROSIS

Keywords